{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneal+Carcinoma",
    "query": {
      "condition": "Peritoneal Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 600,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneal+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:07:37.270Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005029",
      "title": "Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "Up to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005029"
    },
    {
      "nct_id": "NCT00420381",
      "title": "Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Neoplasms",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "enzastaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2007-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420381"
    },
    {
      "nct_id": "NCT00721162",
      "title": "Study of Ramucirumab in Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2008-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-09-26",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 11,
      "location_summary": "Hollywood, Florida • Orlando, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00721162"
    },
    {
      "nct_id": "NCT02759588",
      "title": "GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Carcinomatosis",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genelux Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2016-05",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-05",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Orlando, Florida",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02759588"
    },
    {
      "nct_id": "NCT02082886",
      "title": "HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Peritoneal Neoplasms",
        "Neoplasm Metastasis",
        "Adenocarcinoma",
        "Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Edward-Elmhurst Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 193,
      "start_date": "2014-02",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 2,
      "location_summary": "Elmhurst, Illinois • Naperville, Illinois",
      "locations": [
        {
          "city": "Elmhurst",
          "state": "Illinois"
        },
        {
          "city": "Naperville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082886"
    },
    {
      "nct_id": "NCT04440943",
      "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "MSI-H Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CDX-527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-08-04",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04440943"
    },
    {
      "nct_id": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Mesothelioma; Pleura",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Cholangiocarcinoma",
        "Cholangiocarcinoma Recurrent",
        "Ovarian Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "High Grade Ovarian Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "gavo-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TCR2 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2019-04-15",
      "completion_date": "2028-11-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907852"
    },
    {
      "nct_id": "NCT00107445",
      "title": "EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Peritoneal Cavity Cancer",
        "Stage I Endometrial Carcinoma",
        "Stage I Ovarian Epithelial Cancer",
        "Stage IA Cervical Cancer",
        "Stage IB Cervical Cancer",
        "Stage II Endometrial Carcinoma",
        "Stage II Ovarian Epithelial Cancer",
        "Stage IIA Cervical Cancer",
        "Stage IIB Cervical Cancer",
        "Stage III Cervical Cancer",
        "Stage III Endometrial Carcinoma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2005-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107445"
    },
    {
      "nct_id": "NCT02996825",
      "title": "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mirvetuximab Soravtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 44,
      "start_date": "2017-03-22",
      "completion_date": "2024-02-09",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Upland, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996825"
    },
    {
      "nct_id": "NCT01175343",
      "title": "RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2010-07",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-05-22T03:07:37.270Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01175343"
    }
  ]
}